Market research
HIKAL.NSE Hikal Limited
NSE INR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 28B
- P/E ratio
- Not available
- Analyst target
- 300
- Dividend yield
- 0.0%
- Beta
- 0.34
Profile
Company facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE475B01022
- Market cap
- 28B
- P/E ratio
- Not available
- Analyst target
- 300
- Dividend yield
- 0.0%
- Beta
- 0.34
About
About Hikal Limited
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals industries. The company operates in two segments, Pharmaceuticals and Crop Protection. It provides anti-convulsant, anti-inflammatory, analgesic, anti-parasitic, anti-lipemic, anti-histaminic, anti-depressant, anti-psychotic, anti-emetic, anti-diabetic, anti-thrombotic, anti-viral, and haemorheologic products; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, insecticide, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. The company also manufactures pesticides and herbicides, including diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. In addition, it engages in contract research, custom synthesis, and custom manufacturing of intermediates and active pharmaceutical ingredients. The company operates in India, the United States, Canada, Europe, South East Asia, and internationally. The company was formerly known as Hikal Chemical Industries Ltd. and changed its name to Hikal Limited in April 2000. Hikal Limited was incorporated in 1988 and is based in Navi Mumbai, India.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the HIKAL.NSE discussion.
5 years, 5 months ago
Hikal Limited is currently in a long term uptrend where the price is trading 125.8% above its 200 day moving average.
From a valuation standpoint, the stock is 72.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.3.
Hikal Limited's total revenue rose by 14.7% to $5B since the same quarter in the previous year.
Its net income has increased by 42.0% to $403M since the same quarter in the previous year.
Finally, its free cash flow fell by 45.2% to $660M since the same quarter in the previous year.
Based on the above factors, Hikal Limited gets an overall score of 4/5.